» Articles » PMID: 17714947

The Prevalence of Intrinsic Subtypes and Prognosis in Breast Cancer Patients of Different Races

Overview
Journal Breast
Publisher Elsevier
Specialties Endocrinology
Oncology
Date 2007 Aug 24
PMID 17714947
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

A recent report indicated that a high prevalence of basal-like breast tumors (estrogen receptor [ER]-negative, progesterone receptor [PR]-negative, human epidermal growth factor receptor [HER] 2-negative, and cytokeratin 5/6-positive and/or HER1-positive) could contribute to a poor prognosis in African American women with breast cancer. It has been reported that Japanese women with breast cancer have a significantly better survival rate than other races in the USA. These findings suggest that breast cancers in Japanese women have favorable biological characteristics. To clarify this hypothesis, we conducted a cohort study to investigate the prevalence of intrinsic subtypes and prognosis for each subtype in 793 Japanese patients. This study revealed a very low prevalence (only 8%) of basal-like breast tumors with aggressive biological characteristics in Japanese patients. Survival analysis showed a significantly poorer prognosis in patients with basal-like tumors than in those with luminal A tumors (ER- and/or PR-positive, and HER2-negative) with favorable biological characteristics. These findings support the hypothesis that breast cancers in Japanese women have more favorable biological characteristics and a better prognosis than those in other races. In conclusion, the prevalence of basal-like breast tumors could influence the prognosis of breast cancer patients of different races. The prevalence of intrinsic subtypes should be taken into account when analyzing survival data in a multi-racial/international clinical study.

Citing Articles

Molecular subtypes predict the prognosis of male breast cancer: a retrospective cohort study.

Wang M, Liu D, Zhang Z, Dai X, Chen G, Zhu L Transl Breast Cancer Res. 2024; 4:4.

PMID: 38751485 PMC: 11093005. DOI: 10.21037/tbcr-22-24.


Histological spatial analysis on the induction of PD-L1 macrophages by CD8 T cells at the marginal microenvironment of triple-negative breast cancer.

Suzuki K, Ohe R, Kabasawa T, Kitaoka T, Kawai M, Motoi F Breast Cancer. 2023; 30(6):1094-1104.

PMID: 37792212 PMC: 10587303. DOI: 10.1007/s12282-023-01507-9.


Changing Trends in Estrogen Receptors/Progesterone Receptors/Human Epidermal Growth Factor Receptor 2 Prevalence Rates Among Jordanian Patients With Breast Cancer Over the Years.

Alsughayer A, Dabbagh T, Abdel-Razeq R, Al-Jussani G, Alhassoon S, Sughayer M JCO Glob Oncol. 2022; 8:e2100359.

PMID: 35436143 PMC: 9302262. DOI: 10.1200/GO.21.00359.


Oral Contraceptive Use and Breast Cancer Risk Assessment: A Systematic Review and Meta-Analysis of Case-Control Studies, 2009-2020.

Baranska A, Blaszczuk A, Kanadys W, Malm M, Drop K, Polz-Dacewicz M Cancers (Basel). 2021; 13(22).

PMID: 34830807 PMC: 8616467. DOI: 10.3390/cancers13225654.


Bevacizumab Plays a double-edged role in Neoadjuvant Therapy for Non-metastatic Breast Cancer: A Systemic Review and Meta-Analysis.

Chen X, Gao Y, Zhang G, Li B, Ma T, Ma Y J Cancer. 2021; 12(9):2643-2653.

PMID: 33854624 PMC: 8040714. DOI: 10.7150/jca.53303.